 Recognized revenue of 29.4 million Six assets in the Companys milestone and royalty portfolio advanced to Phase 2 clinical development Completed 24.6 million Series A Perpetual Preferred Stock offering paying a 8.625 dividend Ended 2020 with 84.2 million in cash 